Integrated Genome and Protein Editing Swaps α-2,6 Sialylation for α-2,3 Sialic Acid on Recombinant Antibodies from CHO

Biotechnology Journal

Volumn 12, Issue 2, 2017, Pages

  Chung, Cheng Yu ^a   Wang, Qiong ^a   Yang, Shuang ^b   Yin, Bojiao ^a   Zhang, Hui ^b   Betenbaugh, Michael ^a  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CHO cells; Glycoengineering; Monoclonal Antibody; 2,6 Sialylation; 2,3 Sialylation

Indexed keywords

CARBOXYLIC ACIDS; CELL CULTURE; CYTOTOXICITY; MONOCLONAL ANTIBODIES; POLYSACCHARIDES; RECOMBINANT PROTEINS;

ANTI-INFLAMMATORIES; ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITIES; CHINESE HAMSTER OVARY CELLS; CHO CELL; GLYCOENGINEERING; RECOMBINANT ANTIBODY; SIALYLATION; STRUCTURAL VARIATIONS;

GLYCOSYLATION;

FC RECEPTOR; IMMUNOGLOBULIN G; LECTIN; RECOMBINANT ANTIBODY; SIALIDASE; SIALYLTRANSFERASE; SMALL INTERFERING RNA; MONOCLONAL ANTIBODY; N ACETYLNEURAMINIC ACID; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIBODY ENGINEERING; ARTICLE; CHO CELL LINE; CLONE; COMPARATIVE STUDY; CONTROLLED STUDY; CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; FEMALE; GENE DISRUPTION; GENE EDITING; GENE MUTATION; GENE OVEREXPRESSION; GLYCOSYLATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; SIALYLATION; ST3GAL4 GENE; ST3GAL6 GENE; ANIMAL; BIOENGINEERING; CHEMISTRY; CRICETULUS; GENETICS; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOENGINEERING; CHO CELLS; CRICETULUS; N-ACETYLNEURAMINIC ACID; RECOMBINANT PROTEINS;

EID: 85010644597     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201600502     Document Type: Article

References (30)

1. Ecker, D. M., Jones, S. D., Levine, H. L., The therapeutic monoclonal antibody market. MAbs 2015, 7, 9–14.
2. Strome, S. E., Sausville, E. A., Mann, D., A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007, 12, 1084–1095.
3. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E. et al., The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278, 3466–3473.
4. Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y. et al., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277, 26733–26740.
5. Kurogochi, M., Mori, M., Osumi, K., Tojino, M. et al., Glycoengineered monoclonal antibodies with homogeneous glycan (M3, G0, G2, and A2) using a chemoenzymatic approach have different affinities for FcgammaRIIIa and variable antibody-dependent cellular cytotoxicity activities. PLoS One 2015, 10, e0132848.
6. Lin, C. W., Tsai, M. H., Li, S. T., Tsai, T. I. et al., A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc. Natl. Acad. Sci. USA 2015, 112, 10611–10616.
7. Kaneko, Y., Nimmerjahn, F., Ravetch, J. V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313, 670–673.
8. Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N. et al., Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320, 373–376.
9. Huang, W., Giddens, J., Fan, S. Q., Toonstra, C., Wang, L. X., Chemo enzymatic glycoengineering of intact IgG antibodies for gain of functions. J. Am. Chem. Soc. 2012, 134, 12308–12318.
10. Giddens, J. P., Wang, L. X., Chemoenzymatic glyco-engineering of monoclonal antibodies. Methods Mol. Biol. 2015, 1321, 375–387.
11. Wurm, F. M., Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22, 1393–1398.
12. Lund, J., Takahashi, N., Pound, J. D., Goodall, M., Jefferis, R., Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 1996, 157, 4963–4969.
13. Raymond, C., Robotham, A., Spearman, M., Butler, M. et al., Production of alpha2,6-sialylated IgG1 in CHO cells. MAbs 2015, 7, 571–583.
14. Yu, X., Baruah, K., Harvey, D. J., Vasiljevic, S. et al., Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J. Am. Chem. Soc. 2013, 135, 9723–9732.
15. Otani, M., Kuroki, A., Kikuchi, S., Kihara, M. et al., Sialylation determines the nephritogenicity of IgG3 cryoglobulins. J. Am. Soc. Nephrol. 2012, 23, 1869–1878.
16. Xu, X., Nagarajan, H., Lewis, N. E., Pan, S. et al., The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat. Biotechnol. 2011, 29, 735–741.
17. Jassal, R., Jenkins, N., Charlwood, J., Camilleri, P. et al., Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase. Biochem. Biophys. Res. Commun. 2001, 286, 243–249.
18. Chung, C. Y., Yin, B., Wang, Q., Chuang, K. Y. et al., Assessment of the coordinated role of ST3GAL3, ST3GAL4 and ST3GAL6 on the alpha2,3 sialylation linkage of mammalian glycoproteins. Biochem. Biophys. Res. Commun. 2015, 463, 211–215.
19. Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V. et al., Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013, 8, 2281–2308.
20. Ronda, C., Pedersen, L. E., Hansen, H. G., Kallehauge, T. B. et al., Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool. Biotechnol. Bioeng. 2014, 111, 1604–1616.
21. Yin, B., Gao, Y., Chung, C. Y., Yang, S. et al., Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N-glycan branching and sialylation. Biotechnol. Bioeng. 2015, 112, 2343–2351.
22. Dodev, T. S., Karagiannis, P., Gilbert, A. E., Josephs, D. H. et al., A tool kit for rapid cloning and expression of recombinant antibodies. Sci. Rep. 2014, 4, 5885.
23. Hara, S., Yamaguchi, M., Takemori, Y., Nakamura, M., Ohkura, Y., Highly sensitive determination of N-acetyl- and N-glycolylneuraminic acids in human serum and urine and rat serum by reversed-phase liquid chromatography with fluorescence detection. J. Chromatogr. 1986, 377, 111–119.
24. Yang, S., Li, Y., Shah, P., Zhang, H., Glycomic analysis using glycoprotein immobilization for glycan extraction. Anal. Chem. 2013, 85, 5555–5561.
25. Yang, S., Wang, M., Chen, L., Yin, B. et al., QUANTITY: An isobaric tag for quantitative glycomics. Sci. Rep. 2015, 5, 17585.
26. Kitagawa, H., Paulson, J. C., Cloning of a novel alpha 2,3-sialyltransferase that sialylates glycoprotein and glycolipid carbohydrate groups. J. Biol. Chem. 1994, 269, 1394–1401.
27. Okajima, T., Fukumoto, S., Miyazaki, H., Ishida, H. et al., Molecular cloning of a novel alpha2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids. J. Biol. Chem. 1999, 274, 11479–11486.
28. Yang, Z., Wang, S., Halim, A., Schulz, M. A. et al., Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nat. Biotechnol. 2015, 33, 842–844.
29. Mimura, Y., Kelly, R. M., Unwin, L., Albrecht, S. et al., Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines. J. Immunol. Methods 2016, 428, 30–36.
30. Fiebiger, B. M., Maamary, J., Pincetic, A., Ravetch, J. V., Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc. Natl. Acad. Sci. USA 2015, 112, E2385–2394.